메뉴 건너뛰기




Volumn 51, Issue 6, 1996, Pages 647-653

Orphan drugs: A problem of public health and an economic stake;LES MEDICAMENTS ORPHELINS: PROBLEME DE SANTE PUBLIQUE ET ENJEUX ECONOMIQUES

Author keywords

Legislation; Orphan drug; Rare disease; Tropical disease

Indexed keywords

ALPHA2A INTERFERON; BOTULINUM TOXIN; CAFFEINE; CLOFAZIMINE; DIGOXIN ANTIBODY; ERYTHROPOIETIN; MEFLOQUINE; MODAFINIL; ORPHAN DRUG; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID;

EID: 0030276363     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (3)

References (40)
  • 1
    • 0022322074 scopus 로고
    • The development of orphan drugs. A pharmaceutical company perspective
    • Stucki JC. The development of orphan drugs. A pharmaceutical company perspective. Prog Clin Biol Res 1985; 197: 95-104.
    • (1985) Prog Clin Biol Res , vol.197 , pp. 95-104
    • Stucki, J.C.1
  • 2
    • 12644284390 scopus 로고    scopus 로고
    • Health promotion and disease prevention amendments of 1984
    • Health promotion and disease prevention amendments of 1984. Public Law 98-551.
    • Public Law , pp. 98-551
  • 3
    • 12644315919 scopus 로고
    • The U.S. orphan drug development program: Incentives and results
    • Scheinberg IH, Walshe J.M., eds. Manchester: University Press
    • Finkel MJ. The U.S. orphan drug development program: incentives and results. In: Scheinberg IH, Walshe J.M., eds. Orphan diseases and orphan drugs. Manchester: University Press, 1986: 159-168.
    • (1986) Orphan Diseases and Orphan Drugs , pp. 159-168
    • Finkel, M.J.1
  • 4
    • 0028776178 scopus 로고
    • Rare diseases and orphan drugs
    • Daina E. Rare diseases and orphan drugs. Lancet 1994; 343: 1560-1561.
    • (1994) Lancet , vol.343 , pp. 1560-1561
    • Daina, E.1
  • 7
    • 12644312084 scopus 로고
    • Orphan Drug Act
    • Orphan Drug Act. Public Law 97-414, 1983.
    • (1983) Public Law , pp. 97-414
  • 8
    • 0026032308 scopus 로고
    • The Orphan Drug Act. The first seven years
    • Asbury CH. The Orphan Drug Act. The first seven years. JAMA 1991; 265: 893-897.
    • (1991) JAMA , vol.265 , pp. 893-897
    • Asbury, C.H.1
  • 9
    • 0028596473 scopus 로고
    • Orphan products. Ten years later and then some
    • Haffner ME. Orphan products. Ten years later and then some. Food Drug Law J 1994; 49: 593-601.
    • (1994) Food Drug Law J , vol.49 , pp. 593-601
    • Haffner, M.E.1
  • 10
    • 12644314062 scopus 로고
    • Orphan products
    • Finkel MJ. 'Orphan products'. Ind Sante 1985; 103: 41.
    • (1985) Ind Sante , vol.103 , pp. 41
    • Finkel, M.J.1
  • 11
    • 0022392936 scopus 로고
    • Orphan drugs: The question of products liability
    • Scharf SF. Orphan drugs: The question of products liability. Am J Law Med 1985; 10: 491-513.
    • (1985) Am J Law Med , vol.10 , pp. 491-513
    • Scharf, S.F.1
  • 12
    • 0023040109 scopus 로고
    • Drugs that wouldn't die
    • Weintraub M, Northington FK. Drugs that wouldn't die. JAMA 1986; 255: 2327-2328.
    • (1986) JAMA , vol.255 , pp. 2327-2328
    • Weintraub, M.1    Northington, F.K.2
  • 13
    • 0028242592 scopus 로고
    • Unique aspects of orphan drug safety
    • Affner ME. Unique aspects of orphan drug safety. Drug Inf J 1994; 28: 489-494.
    • (1994) Drug Inf J , vol.28 , pp. 489-494
    • Affner, M.E.1
  • 14
    • 0028239459 scopus 로고
    • Current status of orphan disease drug development
    • Thoene JG. Current status of orphan disease drug development. Curr Opin Pediatr 1994; 6: 209-212.
    • (1994) Curr Opin Pediatr , vol.6 , pp. 209-212
    • Thoene, J.G.1
  • 15
    • 0027437241 scopus 로고
    • The Orphan Drug Act. Should it be changed?
    • Sanders CA. The Orphan Drug Act. Should it be changed? Arch Int Med 1993; 153: 2623-2625.
    • (1993) Arch Int Med , vol.153 , pp. 2623-2625
    • Sanders, C.A.1
  • 16
    • 0027139178 scopus 로고
    • Senators seek reform of Orphan Drug Act
    • Seachrist L. Senators seek reform of Orphan Drug Act. J Natl Cancer Inst 1993; 85: 1984-1985.
    • (1993) J Natl Cancer Inst , vol.85 , pp. 1984-1985
    • Seachrist, L.1
  • 17
    • 12644301120 scopus 로고
    • Partial revision of the Pharmaceutical Affairs Law
    • June 4
    • Akimoto T. Partial revision of the Pharmaceutical Affairs Law. JPMA Update no 4: 3-6; June 4, 1993.
    • (1993) JPMA Update , vol.4 , pp. 3-6
    • Akimoto, T.1
  • 18
    • 12644305806 scopus 로고    scopus 로고
    • note
    • Loi du 8 décembre 1992, modifiant le livre V du code de la santé publique et relative à la pharmacie et au médicament (J.O. du 12/12/1992).
  • 19
    • 12644304799 scopus 로고    scopus 로고
    • note
    • Décrêt no 94-568 du 8 Juillet 1994, relatif aux autorisations temporaires d'utilisation de certains médicaments à usage humain et modifiant le code de la sante publique. (J.O. du 10/07/1994).
  • 20
    • 12644277301 scopus 로고
    • Les médicaments compassionnels, orphelins et importés
    • La Loi, le médicament, le Pharmacien Hospitalier
    • Chevalier A. Les médicaments compassionnels, orphelins et importés. In: La Loi, le médicament, le Pharmacien Hospitalier. Onzième journée APHM 1994: 25-28.
    • (1994) Onzième Journée APHM , pp. 25-28
    • Chevalier, A.1
  • 21
    • 12644287459 scopus 로고    scopus 로고
    • note
    • Directive 91/507/CEE du conseil du 19 Juillet 1991 (J.O.C.E. L-214 du 26 Septembre 1991).
  • 22
    • 12644292826 scopus 로고    scopus 로고
    • Médicaments orphelins. Bientôt une politique européenne
    • Anonyme. Médicaments orphelins. Bientôt une politique européenne. D & P Actualités 1996; 7: 7-10.
    • (1996) D & P Actualités , vol.7 , pp. 7-10
  • 23
    • 12644253745 scopus 로고
    • Bientôt un statut pour les orphelins?
    • Tutin C. Bientôt un statut pour les orphelins? Abstract Hôpital 1995; 52: 8-10.
    • (1995) Abstract Hôpital , vol.52 , pp. 8-10
    • Tutin, C.1
  • 24
    • 0022315211 scopus 로고
    • Current activities and future goals of orphan disease agences
    • Van Woert MH. Current activities and future goals of orphan disease agences. Prog Clin Biol Res 1985; 197: 3-6.
    • (1985) Prog Clin Biol Res , vol.197 , pp. 3-6
    • Van Woert, M.H.1
  • 25
    • 12644296910 scopus 로고
    • Biotechnology receives special attention in budget
    • Miller D. Biotechnology receives special attention in budget. PMA Newslett 1990; 32: 3.
    • (1990) PMA Newslett , vol.32 , pp. 3
    • Miller, D.1
  • 26
    • 0025869216 scopus 로고
    • Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease
    • Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470.
    • (1991) N Engl J Med , vol.324 , pp. 1464-1470
    • Barton, N.W.1    Brady, R.O.2    Dambrosia, J.M.3
  • 27
    • 0026441201 scopus 로고
    • No price too high?
    • Garber AM. No price too high? N Engl J Med 1992; 327: 1676-1678.
    • (1992) N Engl J Med , vol.327 , pp. 1676-1678
    • Garber, A.M.1
  • 29
    • 0029101015 scopus 로고
    • Dornase-alpha and orphan drugs
    • Collier J. Dornase-alpha and orphan drugs. Lancet 1995; 346: 633.
    • (1995) Lancet , vol.346 , pp. 633
    • Collier, J.1
  • 30
    • 0024961138 scopus 로고
    • Big first scored with nerve diseases
    • Lewin R. Big first scored with nerve diseases. Science 1989; 345: 467.
    • (1989) Science , vol.345 , pp. 467
    • Lewin, R.1
  • 31
    • 33947733705 scopus 로고
    • Buying into the orphan drug market
    • Anonymous. Buying into the orphan drug market. Lancet 1995; 346 (8980): 917.
    • (1995) Lancet , vol.346 , Issue.8980 , pp. 917
  • 34
    • 0024446283 scopus 로고
    • Human growth hormone is not an orphan
    • Frasier D. Human growth hormone is not an orphan. N Engl J Med 1989; 321: 1124.
    • (1989) N Engl J Med , vol.321 , pp. 1124
    • Frasier, D.1
  • 35
    • 12644266261 scopus 로고    scopus 로고
    • Amgen, Inc. v Chugai Pharmaceutical Company and Genetics Institute, 1989, WL 169006 (D Mass) and 13 USPQ 2, 1737
    • Amgen, Inc. v Chugai Pharmaceutical Company and Genetics Institute, 1989, WL 169006 (D Mass) and 13 USPQ 2, 1737.
  • 36
    • 12644280741 scopus 로고    scopus 로고
    • note
    • Hearings before the House Subcommittee on Health and the Environment, 101st Cong., 2nd Sess. (February 7, 1990) (Testimony of Thomas Wiggans).
  • 37
    • 0024025761 scopus 로고
    • Are orphan products program funds underused by nuclear medicine reseachers?
    • Harby K. Are orphan products program funds underused by nuclear medicine reseachers? J Nucl Med 1988; 29: 1011-1012.
    • (1988) J Nucl Med , vol.29 , pp. 1011-1012
    • Harby, K.1
  • 38
    • 0028330887 scopus 로고
    • Drugs bill to rein in profits
    • Gershon D. Drugs bill to rein in profits. Nature 1994; 368: 381.
    • (1994) Nature , vol.368 , pp. 381
    • Gershon, D.1
  • 39
    • 0028788896 scopus 로고
    • The economics of orphan drug policy in the US: Can the legislation be improved?
    • Peabody JW. Ruby A, Cannon P. The economics of orphan drug policy in the US: can the legislation be improved? Pharmacoeconomics 1995; 8: 374-384.
    • (1995) Pharmacoeconomics , vol.8 , pp. 374-384
    • Peabody, J.W.1    Ruby, A.2    Cannon, P.3
  • 40
    • 0027848806 scopus 로고
    • The orphan drug regulation and related issues
    • Levitt JA, Kelsey JV. The orphan drug regulation and related issues. Food Drug Law J 1993; 48: 525-532.
    • (1993) Food Drug Law J , vol.48 , pp. 525-532
    • Levitt, J.A.1    Kelsey, J.V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.